Inquiry Basket
Loading ......
OKT3, also known as muromonab-CD3, is a murine monoclonal antibody that targets the CD3 epsilon chain of the T-cell receptor complex. As the first monoclonal antibody approved for human therapeutic use, OKT3 holds a historic place in the development of biologic therapies. Its mechanism of action involves binding to CD3 on the surface of T lymphocytes, leading to T-cell activation followed by prolonged T-cell depletion. This immunosuppressive effect has been utilized for the prevention and treatment of acute rejection in solid organ transplantation.OKT3 therapy is associated with significant adverse effects, most notably cytokine release syndrome, which results from the initial T-cell activation that precedes T-cell depletion. Other adverse events include fever, chills, headache, and in rare cases, pulmonary edema. These toxicities have limited the widespread clinical use of OKT3, but the drug remains an important option for steroid-resistant rejection and as a tool for understanding T-cell directed immunotherapy. As a murine antibody, OKT3 presents unique bioanalytical considerations including higher immunogenicity potential compared to humanized or fully human antibodies. Additionally, OKT3 exerts its effect through binding to CD3 on T cells, necessitating differentiation between free drug and drug bound to its target.
Figure 1.Reliable OKT3 ELISA Kit for Preclinical and Clinical Bioanalysis.
OKT3's unique mechanism of action and murine antibody origin create distinct analytical complexities that demand specialized ELISA detection systems. Unlike humanized therapeutic antibodies, murine OKT3 is highly immunogenic in human subjects, frequently inducing ADA production that alters drug bioavailability, efficacy, and safety profiles. Traditional detection methods fail to resolve three critical analytical dimensions essential for reliable OKT3 research data. First, only free unbound OKT3 retains biological activity capable of targeting CD3 complexes and modulating T-cell function, making free drug concentration the core PD biomarker for evaluating immunosuppressive efficacy. Second, total OKT3 levels reflect overall systemic drug exposure, supporting accurate PK parameter calculation including half-life, clearance, and dose-response correlation. Third, anti-OKT3 antibodies directly drive drug neutralization, accelerated clearance, and adverse immune reactions, requiring rigorous immunogenicity monitoring for clinical safety assessment. Generic ELISA tools cannot distinguish these drug states or eliminate matrix interference from endogenous human immunoglobulins, resulting in unreliable and non-reproducible experimental data. Our three-panel OKT3 ELISA portfolio resolves these limitations, providing full-spectrum bioanalytical coverage for OKT3 preclinical and clinical research.
T lymphocytes are the primary mediators of allograft rejection in solid organ transplantation. Recipient T cells recognize donor-derived alloantigens presented by antigen-presenting cells, leading to T-cell activation, proliferation, and differentiation into effector cells that attack the transplanted organ. CD4-positive helper T cells orchestrate the immune response, while CD8-positive cytotoxic T cells directly damage graft tissue through release of perforin and granzymes. The CD3 complex is an essential component of the T-cell receptor signaling apparatus. Composed of four distinct polypeptide chains (CD3 gamma, delta, epsilon, and zeta), the CD3 complex transduces activation signals upon engagement of the T-cell receptor with antigen. Targeting CD3 provides a means to modulate T-cell function at the most proximal step of the activation cascade.
OKT3 binds specifically to the CD3 epsilon chain on the surface of mature T lymphocytes. Upon binding, the antibody crosslinks CD3 molecules, triggering a signaling cascade that initially activates T cells. This activation phase, lasting approximately thirty to sixty minutes, results in the release of pro-inflammatory cytokines including tumor necrosis factor-alpha, interferon-gamma, and interleukin-2 and interleukin-6. This cytokine release is responsible for the acute clinical syndrome observed following OKT3 administration. Following the initial activation phase, T cells become refractory to further stimulation. Prolonged exposure to OKT3 leads to internalization and degradation of the CD3-T-cell receptor complex, effectively removing the receptor from the T-cell surface. This process results in functional T-cell depletion, rendering the cells unable to respond to alloantigens. The net effect is profound immunosuppression that prevents graft rejection.
| Bioanalytical Monitoring of OKT3 | Details |
| Distinguishing Free vs Total Drug | OKT3 exerts its immunosuppressive effect by binding to CD3 on T cells. Following administration, OKT3 exists in two forms. Free drug refers to the antibody that has not yet bound to CD3, representing the pharmacologically active species available to engage new T cells. Total drug includes both free drug and drug bound to CD3 on T cells or soluble CD3. The Free OKT3 ELISA Kit measures unbound drug that is available for target engagement. This measurement is most relevant for understanding immediate pharmacologic activity and for correlating drug exposure with T-cell depletion. The Total OKT3 ELISA Kit measures both free and bound drug, providing a comprehensive assessment of overall drug exposure regardless of target engagement status. |
| Immunogenicity Assessment | As a murine monoclonal antibody, OKT3 has high immunogenicity potential. Most patients who receive OKT3 develop anti-OKT3 antibodies, which can neutralize the drug, accelerate its clearance, and reduce efficacy. The Anti-OKT3 ELISA Kit enables detection and characterization of these anti-drug antibody responses. |
| Product Overview | Details |
| Free OKT3 ELISA Kit | The Free OKT3 ELISA Kit is specifically designed for the quantitative determination of unbound OKT3 concentrations in human serum or plasma. This kit measures the pharmacologically active fraction of drug available for CD3 binding. Applications
|
| Total OKT3 ELISA Kit | The Total OKT3 ELISA Kit utilizes a robust sandwich ELISA format to quantify all circulating OKT3 species, including free active drug, CD3-bound drug, and ADA-complexed inactive drug. The microplate is pre-coated with high-affinity capture antibodies targeting the conserved Fc region of murine IgG2a, enabling universal binding of all intact OKT3 molecules regardless of their binding status. Applications
|
OKT3 holds a historic place in the development of therapeutic monoclonal antibodies as the first approved agent of its class. While its clinical use has diminished, OKT3 remains an important research tool and a reference standard for T-cell depletion strategies. The unique bioanalytical requirements of OKT3—including differentiation between free and total drug and assessment of immunogenicity—necessitate specialized ELISA solutions. The Free OKT3 ELISA Kit measures the pharmacologically active fraction available for T-cell engagement. The Total OKT3 ELISA Kit provides comprehensive exposure assessment including both free and CD3-bound drug. The Anti-OKT3 ELISA Kit enables reliable immunogenicity detection, particularly important given the murine origin of OKT3. Together, these three kits provide a complete bioanalytical toolkit for researchers working with OKT3 in preclinical and clinical settings.
| Cat. No. | Product Name | Species Reactivity | Detection Method | |
| DEIA-JY25025 | Free OKT3 ELISA Kit | Human | ELISA | Inquiry |
| DEIA-JY25043 | Total OKT3 ELISA Kit | Human | ELISA | Inquiry |
| DEIA-JY25061 | Anti-OKT3 ELISA Kit | Human | ELISA | Inquiry |
Loading ......
